-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

30 Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866)

Myeloma: Therapy, excluding Transplantation
Program: Oral and Poster Abstracts
Type: Oral
Session: 653. Myeloma: Therapy, excluding Transplantation: Advances in Newly Diagnosed and Relapsed Myeloma
Saturday, December 5, 2015: 8:45 AM
Tangerine 2 (WF2), Level 2 (Orange County Convention Center)

Wee-Joo Chng1, Hartmut Goldschmidt2, Meletios A. Dimopoulos3, Philippe Moreau4*, Douglas Joshua5, Antonio Palumbo6, Thierry Facon7, Heinz Ludwig8, Ludek Pour, MD9*, Ruben Niesvizky10, Albert Oriol, MD11*, Laura Rosinol12*, Aleksandr Suvorov13*, Gianluca Gaidano14, Tomas Pika15*, Katja Weisel16*, Vesselina Goranova-Marinova17*, Heidi H. Gillenwater18, Nehal Mohamed18*, Shibao Feng18* and Roman H�jek19

1National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
2Heidelberg Medical University, Heidelberg, Germany
3National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4University of Nantes, Nantes, France
5Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
6University of Torino, Torino, Italy
7CHRU Lille Hopital Claude Huriez, Lille, France
8Department of Medicine I, Wilhelminenhospital, Wilhelminen Cancer Research Institute, Vienna, Austria
9University Hospital Brno, Brno, Czech Republic
10Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY
11Institut Catal� d�Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
12Hospital Cl�nic de Barcelona, Barcelona, Spain
13First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia
14Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
15University Hospital Olomouc, Olomouc, Czech Republic
16Universitatsklinikum Tubingen, Tubingen, Germany
17Hematology Clinic University Multiprofile Hospital for Active Treatment, Plovdiv, Bulgaria
18Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA
19University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic

Introduction: Single-agent carfilzomib has previously shown activity in patients with relapsed and refractory multiple myeloma (MM) who have high-risk cytogenetic abnormalities (Jakubowiak et al, Leukemia 2013;27:2351�56). In the randomized phase 3 study ENDEAVOR (NCT01568866; N=929), carfilzomib plus dexamethasone (Kd) demonstrated a clinically meaningful and statistically significant 2-fold improvement in median progression-free survival (PFS) compared with bortezomib plus dexamethasone (Vd; 18.7 vs 9.4 months; hazard ratio [HR]: 0.53; 95% confidence interval [CI]: 0.44�0.65; P<.0001) (Dimopoulos et al, J Clin Oncol 2015;33:abstr 8509; Dimopoulos et al, Haematologica 2015;100[s1]:abstr LB2071). Herein we present results of a preplanned subgroup analysis of the efficacy and safety of Kd vs Vd in the ENDEAVOR study based on baseline cytogenetic risk status.

Methods: Adult patients with relapsed MM (RMM; 1�3 prior lines of therapy) were eligible. Patients in the Kd arm received carfilzomib (30-minute intravenous [IV] infusion) on days 1, 2, 8, 9, 15, and 16 (20 mg/m2 on days 1 and 2 of cycle 1; 56 mg/m2 thereafter) and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of a 28-day cycle. Patients in the Vd arm received bortezomib 1.3 mg/m2 (IV bolus or subcutaneous injection) on days 1, 4, 8, and 11 and dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of a 21-day cycle. Cycles were repeated until disease progression, withdrawal of consent, or unacceptable toxicity. The primary end point was PFS. Secondary end points included overall survival, overall response rate (ORR), duration of response (DOR), rate of grade ≥2 peripheral neuropathy (PN), and safety. Fluorescence in situ hybridization was used to assess cytogenetic risk status. The high-risk group was defined as those patients with the genetic subtypes t(4;14) or t(14;16) in ≥10% of screened plasma cells, or deletion 17p in ≥20% of screened plasma cells based on central review of bone marrow samples obtained at study entry; the standard-risk group consisted of patients without these genetic subtypes.

Results: A total of 929 patients were randomized (Kd: 464; Vd: 465). Baseline cytogenetic risk status was well-balanced between the treatment arms (high-risk: Kd, 20.9%; Vd, 24.3%; standard-risk: Kd, 61.2%; Vd, 62.6%; unknown: Kd, 17.9%; Vd, 13.1%). Efficacy end points by baseline cytogenetic risk status are presented in the Table; Kaplan-Meier PFS curves by baseline cytogenetic risk status are shown in the Figure. Median PFS in the high-risk group (n=210) was 8.8 months (95% CI: 6.9�11.3) for Kd vs 6.0 months (95% CI: 4.9�8.1) for Vd (HR: 0.646; 95% CI: 0.453�0.921). Median PFS in the standard-risk group (n=575) was not estimable for Kd (95% CI: 18.7�not estimable) vs 10.2 months (95% CI: 9.3�12.2) for Vd (HR: 0.439; 95% CI: 0.333�0.578). ORRs (≥partial response) were 72.2% (Kd) vs 58.4% (Vd) in the high-risk group and 79.2% (Kd) vs 66.0% (Vd) in the standard-risk group. In the high-risk group, 15.5% (Kd) vs 4.4% (Vd) achieved a complete response (CR) or better. In the standard-risk group, 13.0% (Kd) vs 7.9% (Vd) achieved ≥CR. Median DOR in the high-risk group was 10.2 months for Kd vs 8.3 months for Vd. Median DOR in the standard-risk group was not estimable for Kd vs 11.7 months for Vd. Grade ≥3 adverse events (AEs) were reported at higher rates with Kd vs Vd in the high- and standard-risk groups (70.1% vs 63.1% and 73.9% vs 68.3%). Rates of grade ≥3 AEs of interest by baseline cytogenetic risk status are shown in the Table. Grade ≥2 PN was reported at lower rates with Kd vs Vd in the high-risk group (3.1% vs 35.1%; odds ratio: 0.059; 95% CI: 0.018�0.198) and also in the standard-risk group (6.4% vs 33.4%; odds ratio: 0.135; 95% CI: 0.079�0.231). �

Conclusion: As expected, median PFS for patients with high-risk cytogenetics was lower compared with the overall population; however, patients treated with Kd had a clinically meaningful improvement in PFS compared with Vd in patients with high- or standard-risk cytogenetics. Higher response rates, a greater depth of response, and longer DOR were also observed with Kd vs Vd across cytogenetic subgroups. Kd had a favorable benefit�risk profile in patients with high-risk relapsed MM, and was superior to Vd, regardless of baseline cytogenetic risk status.

 

 

 

 

 

 

Disclosures: Goldschmidt: BMS: Consultancy , Research Funding ; Amgen, Takeda: Consultancy ; Onyx: Consultancy , Honoraria ; Janssen, Celgene, Novartis: Consultancy , Honoraria , Research Funding ; Chugai, Millennium: Honoraria , Research Funding . Dimopoulos: Onyx: Honoraria ; Janssen: Honoraria ; Celgene: Honoraria ; Janssen-Cilag: Honoraria ; Genesis: Honoraria ; Amgen: Honoraria ; Novartis: Honoraria . Moreau: Novartis, Janssen, Celgene, Millennium, Onyx Pharmaceuticals: Consultancy , Honoraria . Joshua: Celgene: Membership on an entity�s Board of Directors or advisory committees . Palumbo: Novartis, Sanofi Aventis: Honoraria ; Celgene, Millennium Pharmaceuticals, Amgen, Bristol-Myers Squibb, Genmab, Janssen-Cilag, Onyx Pharmaceuticals: Consultancy , Honoraria . Facon: Onyx/Amgen: Membership on an entity�s Board of Directors or advisory committees . Ludwig: Celgene Corporation: Honoraria , Speakers Bureau ; Onyx: Honoraria , Speakers Bureau ; Bristol Myers Squibb: Honoraria , Speakers Bureau ; Janssen Cilag: Honoraria , Speakers Bureau ; Takeda: Research Funding . Niesvizky: Celgene, Millennium, Onyx: Consultancy , Speakers Bureau . Oriol: Celgene, Janssen, Amgen: Consultancy , Speakers Bureau . Rosinol: Celgene, Janssen: Honoraria . Gaidano: Morphosys, Roche, Novartis, GlaxoSmith Kline, Amgen, Janssen, Karyopharm: Honoraria , Other: Advisory Boards ; Celgene: Research Funding . Weisel: Takeda: Other: Travel Support ; Novartis: Other: Travel Support ; Onyx: Consultancy , Honoraria ; Janssen: Consultancy , Honoraria , Other: Travel Support , Research Funding ; Amgen: Consultancy , Honoraria , Other: Travel Support ; Celgene: Consultancy , Honoraria , Other: Travel Support , Research Funding ; Bristol Myers Squibb: Consultancy , Honoraria , Other: Travel Support ; Noxxon: Consultancy . Gillenwater: Onyx, Amgen: Employment , Other: Stock . Mohamed: Onyx/Amgen: Employment , Other: Stock . Feng: Amgen/Onyx: Employment , Equity Ownership . H�jek: Janssen-Cilag: Honoraria ; Celgene, Amgen: Consultancy , Honoraria .

<< Previous Abstract | Next Abstract

*signifies non-member of ASH